Abemaciclib + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Dedifferentiated Liposarcoma
Conditions
Advanced Dedifferentiated Liposarcoma
Trial Timeline
Nov 11, 2021 → Dec 1, 2026
NCT ID
NCT04967521About Abemaciclib + Placebo
Abemaciclib + Placebo is a phase 3 stage product being developed by Eli Lilly for Advanced Dedifferentiated Liposarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT04967521. Target conditions include Advanced Dedifferentiated Liposarcoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05940493 | Phase 2 | Recruiting |
| NCT04967521 | Phase 3 | Active |
Competing Products
20 competing products in Advanced Dedifferentiated Liposarcoma